임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
32건 표시
- 2상모집 중· Non-cystic Fibrosis BronchiectasisA Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
리드: 사노피
- 2상모집 중· Hidradenitis SuppurativaA Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
리드: 사노피
- 2상모집 중· Chronic Graft Versus Host DiseaseA Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
리드: 사노피
- 2상모집 중· Hidradenitis SuppurativaBrivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
리드: 사노피
- 2상모집 중· Non-Small Cell Lung CancerA Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
협력: 사노피
- 2상모집 중· Microscopic ColitisA Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
리드: 사노피
- 2상모집 중· Type 1 Diabetes MellitusEfficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
리드: 사노피
- 2상모집 중· Ulcerative ColitisA Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
리드: 사노피
- 2상모집 중· Solid TumorsPhase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
협력: 리제네론, 사노피
- 2상모집 중· Crohn's DiseaseA Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
리드: 사노피
- 2상모집 중· Smouldering MyelomaIsatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
협력: BMS, 사노피
- 2상모집 중· Severe Aplastic AnemiaClinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
협력: 사노피
- 2상모집 중· Colitis UlcerativeA Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
리드: 사노피
- 2상모집 중· Crohn's DiseaseA Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
리드: 사노피
- 2상모집 중· Metastatic Uveal MelanomaStudy of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
협력: 리제네론, 사노피
- 2상모집 중· Bronchiolitis Obliterans SyndromeBElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
협력: 사노피
- 2상모집 중· Relapsed CancerIsatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
협력: GSK, 사노피
- 2상모집 중· Interstitial Lung Disease Due to Systemic DiseasePlatform Clinical Study for Conquering Scleroderma
협력: 사노피
- 2상모집 중· Chronic Graft Versus Host DiseaseBelumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
협력: 사노피
- 2상모집 중· Chronic Graft Versus Host DiseaseBelumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
협력: 사노피
- 2상모집 중· Multiple MyelomaPost-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
협력: 사노피
- 2상모집 중· Multiple MyelomaIsa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
협력: 사노피
- 2상모집 중· Monoclonal GammopathyIsatuximab in Patients With Monoclonal Gammopathy of Renal Significance
협력: 사노피
- 2상모집 중· Multiple MyelomaClinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
협력: 사노피
- 2상모집 중· Juvenile Idiopathic ArthritisA Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
리드: 사노피 · 협력: 리제네론
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.